| Display title | Chemistry:Bevacizumab |
| Default sort key | Bevacizumab |
| Page length (in bytes) | 78,887 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 236738 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>NBrush |
| Date of page creation | 22:35, 5 February 2024 |
| Latest editor | imported>NBrush |
| Date of latest edit | 22:35, 5 February 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Bevacizumab, sold under the brand name Avastin among others, is a monoclonal antibody medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, ovarian cancer, glioblastoma... |
